NJ Adopts More Transparent Prescription Drug Pricing

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • New Jersey AG Matthew Platkin announced the adoption of new rules designed to promote greater transparency in prescription drug pricing.
  • The new rules implement recently enacted legislation intended to control prescription costs by imposing registration, reporting, and compliance requirements on manufacturers, insurance carriers, wholesalers, and other entities, who will be required to provide the AG’s office with information about drugs with significant price increases or high launch prices.
  • The AG’s office will use the reported information to produce an annual report on emerging trends in prescription drug prices, which will be made available on a prescription drug pricing webpage, and to assist the newly created Drug Affordability Council formulate legislative and regulatory policy recommendations on prescription drug affordability.
  • We have previously reported on an amicus brief filed by Democratic AGs in support of a federal drug pricing transparency law.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Cozen O'Connor

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide